Characteristics of patients with slow and regular engraftment after autologous PBSCT
| . | Slow engraftment, > 19 d (n = 27) . | Regular engraftment, 8-19 d (n = 76) . |
|---|---|---|
| Sex, n | ||
| Male | 12 | 56 |
| Female | 15 | 20 |
| Age, y, median (range) | 54 (18-67) | 52 (17-71) |
| Entities | 1 amyloidosis | 1 amyloidosis |
| 1 Ewing sarcoma | 15 germ cell carcinoma | |
| 3 Morbus Hodgkin | 10 Morbus Hodgkin | |
| 17 multiple myeloma | 32 multiple myeloma | |
| 5 NHL | 18 NHL | |
| Engraftment of leukocytes, d, median (range) | 23 (20-41) | 14 (8-19) |
| Engraftment of thrombocytes, d, median (range) | 24 (11-61) | 13 (8-21) |
| CD−34+ cells, 106 kg, median (range) | 6.34 (3.18-19.6) | 6.26 (2.83-14.8) |
| Conditioning regimen | 7 BEAM | 21 BEAM |
| 1 BEAM (without BCNU) | 2 BCNU | |
| 2 melphalan 100 mg | 4 carboplatin/etoposide | |
| 1 treosulfan/melphalan | 2 HD cyclophosphamide | |
| 16 melphalan 200 mg | 31 melphalan 200 mg | |
| 11 P-PEI | ||
| 2 melphalan 100 mg | ||
| 3 CEIAP | ||
| Received chemotherapy cycles, n, median (range) | 5 (3-34) | 5 (0-16) |
| Radiotherapy, yes, n (%) | 9 (33.4) | 34 (44.7) |
| . | Slow engraftment, > 19 d (n = 27) . | Regular engraftment, 8-19 d (n = 76) . |
|---|---|---|
| Sex, n | ||
| Male | 12 | 56 |
| Female | 15 | 20 |
| Age, y, median (range) | 54 (18-67) | 52 (17-71) |
| Entities | 1 amyloidosis | 1 amyloidosis |
| 1 Ewing sarcoma | 15 germ cell carcinoma | |
| 3 Morbus Hodgkin | 10 Morbus Hodgkin | |
| 17 multiple myeloma | 32 multiple myeloma | |
| 5 NHL | 18 NHL | |
| Engraftment of leukocytes, d, median (range) | 23 (20-41) | 14 (8-19) |
| Engraftment of thrombocytes, d, median (range) | 24 (11-61) | 13 (8-21) |
| CD−34+ cells, 106 kg, median (range) | 6.34 (3.18-19.6) | 6.26 (2.83-14.8) |
| Conditioning regimen | 7 BEAM | 21 BEAM |
| 1 BEAM (without BCNU) | 2 BCNU | |
| 2 melphalan 100 mg | 4 carboplatin/etoposide | |
| 1 treosulfan/melphalan | 2 HD cyclophosphamide | |
| 16 melphalan 200 mg | 31 melphalan 200 mg | |
| 11 P-PEI | ||
| 2 melphalan 100 mg | ||
| 3 CEIAP | ||
| Received chemotherapy cycles, n, median (range) | 5 (3-34) | 5 (0-16) |
| Radiotherapy, yes, n (%) | 9 (33.4) | 34 (44.7) |
NHL indicates non-Hodgkin lymphoma; BEAM, BCNU, cytosine arabinoside, etoposide, melphalan; P-PEI, paclitaxel, carboplatin, etoposide, ifosfamide; HD, high dose; and CEIAP, carboplatin, etoposide, ifosfamide, adriamycin, dexamethasone.